This observation led us to propose that a cell-cycle checkpoint, which we call for convenience the fusion checkpoint (FCP), prevents proliferation following accidental fusion, thus making fusion ...

Merck’s Phase III KEYNOTE-B96 trial shows significant overall and progression-free survival gains with Keytruda plus ...

Cancer continues to pose a substantial public health problem in Nigeria, characterized by rising rates of occurrence and mortality. While there is increasing interest in using natural products for ...

Pin1 participates in the regulation of cell-cycle checkpoints and maintains the balance and timing between pro-proliferative and pro-apoptotic signals. Once an oncogenic hit has been sustained ...

GEN2 is well tolerated with minimal toxicity and signs of pharmacodynamic activity in an ongoing Phase 1 dose escalation and ...

ARV-393 is Arvinas’ investigational PROteolysis TArgeting Chimera (PROTAC) degrader targeting the B-cell lymphoma 6 protein (BCL6), a transcriptional repressor and major driver of B-cell lymphomas.

As lead candidate mipletamig continues to outperform efficacy and safety benchmarks in AML trials, APVO711 exemplifies emerging innovation from Aptevo's proprietary ADAPTIR® platformIn preclinical ...

Patients were randomized to receive sasanlimab 300 mg by subcutaneous (SC) injection every four weeks up to cycle 25 (cycle = four ... that functions as an immune checkpoint that negatively regulates ...

Ten (10) patients have achieved an objective response (5 confirmed) when treated with MDNA11 alone or in combination with KEYTRUDA® (pembrolizumab) – all responders had advanced and/or metastatic ...

Inhibition of GSK-3β may inhibit tumor growth and improve survival through several complimentary mechanisms that include enhancement of chemotherapy activity, activation of innate anti-tumor immunity, ...

Some 50,000 Australians will die from cancer this year, despite big breakthroughs in treatments. What makes cancer so very ...